Leiden Dworak - Jul 21, 2023 Form 3 Insider Report for TScan Therapeutics, Inc. (TCRX)

Signature
/s/ Leiden Dworak
Stock symbol
TCRX
Transactions as of
Jul 21, 2023
Transactions value $
$0
Form type
3
Date filed
7/24/2023, 07:31 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TCRX Voting Common Stock 5.69K Jul 21, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCRX Stock Option (Right to Buy) Jul 21, 2023 Voting Common Stock 37.5K $2.90 Direct F1
holding TCRX Stock Option (Right to Buy) Jul 21, 2023 Voting Common Stock 28.8K $1.81 Direct F2
holding TCRX Stock Option (Right to Buy) Jul 21, 2023 Voting Common Stock 164K $2.49 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 4, 2022, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F2 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of February 2, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F3 96,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 67,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.